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Abstract
Coronavirus disease 2019 (COVID-19) is an infection caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). It is known to cause a myriad of symptoms ranging from mild respiratory illness to severe pneumonia
and acute respiratory distress. Since its discovery in late 2019 in Wuhan, China, the virus has caused a devastating
worldwide pandemic. Although COVID-19 most commonly causes respiratory symptoms, complications such as hypercoagulability are now known to occur in some patients. In this case report, we present a COVID-19 patient that
suffered a stroke and was found to have an aortic thrombus. In this case report, we discussed hypercoagulability, venous
and arterial thrombosis in COVID-19 patients. We hope to highlight the importance of monitoring laboratory markers of
hypercoagulability and thromboembolism symptoms in COVID-19 patients and encourage appropriate prophylaxis and
treatment with anticoagulants when necessary. It is unclear whether or not a causal relationship exists given the nature
of the syndrome. However, given the growing number of reported cases physicians should maintain awareness of this
possible complication when evaluating COVID-19 patients.
Keywords: Covid- 19, Complications of COVID-19, Aortic thrombus

1. Introduction

A

s of July, 21, 2021, there have been 191,148,056
conﬁrmed cases and 4,109,303 deaths from
COVID-19 globally, out of which 33,828,878 cases
and 604,252 deaths were in the United States alone.1
Thousands of new cases continue to be reported
daily, even with the widespread vaccination
campaign administered over 55 million doses in the
United States.2 In addition to receiving the vaccination, other preventive techniques continue to be
highly recommended. These include frequent

handwashing, avoiding touching of the eyes, nose,
mouth, social distancing of six feet between people
not from the same household, avoiding contact with
sick individuals, wearing a mask around others, and
daily cleaning of frequently touched surfaces.3 Over
the last one and a half years since the emergence of
the virus in December 2019, clinicians continue to
discover new things about the natural course of
COVID-19. One of the complications that COVID-19
is now known to cause is a hypercoagulable state
with an increased risk of thromboembolism.4
Therefore, clinicians must keep an eye out for this
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complication while managing a COVID-19 patient,
especially if they are at high risk for thrombosis or
when new physical exam ﬁndings or symptoms
arise.

2. Patient presentation
An 83-year-old female with a past medical history
of hypertension, type two diabetes mellitus, hyperlipidemia, and stroke presented to the emergency
department with altered mental status. She was
conversational and alert but oriented only to herself.
Her son reported that she had been acting confused
before admission. On initial examination, she was
found to have a temperature of 39.3  C, heart rate of
107, respiratory rate of 27, BP 156/97, and oxygen
saturation of 91% at room air. In the Emergency
Room (E.R.), the patient was noted to be in atrial
ﬁbrillation on the cardiac monitor. On physical examination, the patient appears to be non-toxic and
in no acute distress. Alert and oriented x1 but
pleasant and conversational., Cardiovascular examination showed Irregular rhythm and tachycardic. S1 and S2 appreciated. No jugular venous
dilation. On respiratory examination scattered
crackles were noted. On neurological examination
motor
strength
and
sensation
symmetric
throughout. Refer to Table 1 for a summary of laboratory results upon admission. Computed tomography (C.T.) chest without contrast revealed
bilateral multifocal opacities with imaging features
typical for COVID-19 infection. Polymerase chain
reaction (PCR) test conﬁrmed the COVID-19 infection. She was started on Lovenox 90 mg subcutaneous injections twice a day due to the paroxysmal
atrial ﬁbrillation. Her home medications included
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aspirin 81 mg, atorvastatin 80 mg, carvedilol, amlodipine, famotidine, and insulin lispro sliding scale.
On her second day of hospitalization, she was alert,
oriented to time, place, and person, and answered
questions coherently (Table 2). She had returned to
her baseline mentation, conﬁrmed by her son via
phone call. During the morning of day three of
hospitalization, she was found to be in sinus
rhythm, so her Lovenox was discontinued, and Eliquis 5 mg twice a day was started. On day seven, the
patient started requiring oxygen therapy via nasal
cannula, and a chest x-ray revealed worsening inﬁltrates. Due to concerns of hospital-acquired
pneumonia, she was started on vancomycin and
Zosyn. On day nine, the patient's mental status
drastically changed; she was signiﬁcantly more
confused and lethargic but arousable. She was
nonverbal and unable to follow commands or
vocalize understanding. Neurological examination
was positive for subtle right facial asymmetry and
droop, right arm ﬂaccidity, with sensation to pain
upon deep stimulation. She could not overcome
gravity with her right upper or lower extremities but
did withdraw to pain. A stroke alert was called.
Repeat D-dimer was 1337 ng/mL DDU (normal
<255 ng/mL DDU). CT scan of the brain without
contrast showed no evidence of intracranial hemorrhage or acute pathology. Severe small vessels
ischemic change in the deep white matter supratentorial and cortical atrophy no other signiﬁcant
interval change from previous C.T. scan of the brain
done upon admission. She had a National Institutes
of Health Stroke Scale of 18. C.T. angiogram of the
head showed no evidence of large vessel intracranial occlusion, but it showed irregularity and

Table 1. Summary of laboratory abnormalities.
Laboratory ﬁndings

Patient's value (normal values)

White blood cell count
Lymphocytes absolute (low)
Potassium (low)
Creatinine (high)
Glucose (high)
Aspartate aminotransferase (high)
Alanine aminotransferase (high)
Procalcitonin (high)
D-dimer (high)
C-reactive protein (high)
Lactate (high)
Erythrocyte sedimentation rate (high)
Ammonia (high)
Portable troponin
B-type natriuretic peptide (high)
Myoglobin, serum (high)
International normalized ratio
Activated partial thromboplastin time (low)
Body Mass Index

4.7 (4.0e11.0 X10E9/L)
0.8 (1.0e3.5 X10E9/L)
3.4 (3.5e5.0 mmol/L)
1.19 (0.40e1.00 mg/dL)
202 (65e99 mg/dL)
60 (0e41 U/L)
38 (0e31 U/L)
0.13 (<0.05 ng/mL)
1439 (<255 ng/mL DDU)
4.6 (0.000e0.744 mg/dL)
3.1 (0.4e2.0 mmol/L)
73 (0e30 mm/h)
60 (11e35 umol/L)
0.07 (0.00e0.09 ng/mL)
178 (<100.0 pg/mL)
107.7 (14.3e65.8 ng/mL)
1.1 (0.8e1.1)
24 (26e37 s)
31.85 kg/m2
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Table 2. Summary of Patient's mental status throughout hospitalization.
Day of Admission

Patient's Mental Status

1 (At presentation)
2

Conversational but alert and oriented only to herself, she had been acting confused per her son.
Alert, oriented to time, place, and person, and answered questions properly. She had returned
to her baseline mentation, conﬁrmed by her son via phone call.
The patient's mental status drastically changed; she was signiﬁcantly more confused and
lethargic but arousable. She was nonverbal and unable to follow commands or vocalize
understanding. Neurological examination was positive for subtle right facial asymmetry
and droop, right arm ﬂaccidity with sensation to pain upon deep stimulation. She could not
overcome gravity with her right upper or lower extremities but did withdraw to pain.
National Institutes of Health Stroke Scale (NIHSS) of 18.
Answered yes and no questions, but her comprehension and mental status were still impaired.
She continued to have aphasia and right-sided weakness.

9

17 (Discharge)

narrowing of the anterior cerebral artery's distal
branches. C.T. angiogram of the chest showed a
mural thrombus in the distal aortic arch extending
into the descending aorta consistent with prior
dissection, as shown in Figs. 1 and 2. The brain's
M.R.I. without contrast showed moderate-sized
acute/subacute ischemic infarction at the left frontal
lobe's medial aspect along with the left anterior cerebral artery distribution. At this time, nurses
shared that the nursing aides noticed that the patient had been spitting out her medications, and
they were not sure if she had been receiving all her
medications. Eliquis was discontinued, and a heparin drip was started. Routine electroencephalogram showed left frontal-temporal dysfunction with
evidence of right temporal cortical dysfunction and
moderate diffuse encephalopathy; no epileptiform
discharges or seizures were seen. She was transitioned to Coumadin as per agreement of vascular
surgery and cardiothoracic surgery. On day seventeen of admission, the patient was discharged to a
skilled nursing facility on Coumadin with the

instructions to follow-up with vascular surgery to
evaluate the need for further surgery. On discharge,
she answered yes and no questions, but her
comprehension and mental status were still
impaired. She continued to have aphasia and rightsided weakness.

3. Discussion
This patient had many risk factors for stroke upon
admission. In addition to the presence of atrial
ﬁbrillation, her history of stroke, type two diabetes
mellitus, and hypertension with her age and gender
make her CHA₂DS₂-Vasc score 7. This score put her
at moderate-high risk for stroke and made her a
candidate for anticoagulation. In addition to this risk,
our patient had a COVID-19 infection, which is
known to cause hypercoagulability. The hypercoagulable state mechanism in a patient with COVID-19
is thought to be due to endothelial damage via direct
invasion, cytokine release, and the activation of
complement pathways; stasis; and hypercoagulable

Fig. 1. Axial Section of the chest CT showing Aortic thrombus.
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Fig. 2. Sagital view of the chest CT showing extension of the aortic thrombus.

state via increased prothrombotic factors.5 A report
published by Panigada et al. provides evidence that
supports the theory of increased prothrombotic factors in patients with COVID-19. They observed a
series of patients admitted to the intensive care unit
whose lab parameters were consistent with a state of
hypercoagulability. These patients were found to
have normal or increased platelet counts, along with
an increase in ﬁbrinogen, D-dimer, C-reactive protein, factor VIII, von Willebrand factor, and protein C
marginally decreased antithrombin6. As a result of
this hypercoagulable state, the incidence of venous
and arterial thromboembolism increases during
COVID-19,7 further increasing the mortality in these
patients. The presence of thrombosis and microangiopathy in the lungs' small vessels and capillaries
has been reported in multiple autopsies performed
on patients who died of COVID-19.8
A study involving 1114 COVID-19 patients at Mass
General Brigham integrated health network
analyzed the incidence of arterial and venous
thromboembolism and their effects on patients
managed in intensive care (n ¼ 170), hospitalized
non-intensive care (n ¼ 229), and outpatient (n ¼ 715)
settings. They found major arterial or venous
thromboembolism, major cardiovascular adverse
events, and symptomatic venous thromboembolism
were highest in the intensive care group (35.3%,
45.9%, 27.0%, respectively). Whereas hospitalized

non-intensive care group had 2.6%, 6.1%, and 2.2%,
respectively, and 0% occurrence in the outpatient
group. Prophylactic anticoagulation was given to
89.4% of the intensive care group and 84.7% of the
hospitalized non-intensive care group, suggesting
that coagulopathy is common among COVID-19
patients with more severe infections.9
Arterial thromboembolism in patients with
COVID-19 is not as well documented in literature as
venous thromboembolism. Arterial thrombosis most
commonly causes myocardial infarction, stroke, and
limb ischemia. In a review performed by Cheruiyot
et al., they assessed 27 studies (5 cohort studies, 5 case
series, and 17 case reports) that reported arterial
thrombotic events in patients with COVID-19. Arterial thromboembolism in critically ill patients treated
in intensive care units was 4.4% in the ﬁve cohort
studies. These events were symptomatic in over 95%
of those patients and involved multiple arteries in
18%. The most commonly involved arteries were
limb arteries (39%), cerebral arteries (24%), great
vessels including the aorta, common iliac, common
carotid, and brachiocephalic trunk (19%), coronary
arteries (9%), and the superior mesenteric artery
(8%). A mortality rate of approximately 20% was reported in these patients.10 Table 3 gives a brief account of similar case reports that chronicle the
occurrences of arterial thromboembolism in patients
with COVID-19.
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Table 3. Locations of arterial thromboembolic events in four COVID-19 case reports.
Study

Number of
Patient Cases

Arterial Locations of Thromboembolic Event

Levolger et al.11

4

Singh et al.12
Lushina et al.13
Kashi et al.14

3
1
7

Common iliac artery, tibial-ﬁbular trunk, subclavian artery, internal carotid, and superior
mesenteric artery
Tibial artery, aorta, popliteal artery, common iliac artery, and left ventricle apex
Distal basilar artery and renal artery
Aorta, popliteal artery, common femoral artery, iliac artery, deep femoral artery,
and femoropopliteal bypass

Table 4. Locations of aortic thrombosis in eight case reports.
Study

Number of
Patient Cases

Aortic Location of Thrombosis (number of patients)a

Kashi et al.14
de Carranza et al.15
Baeza et al.16
Mukherjee et al.17
Gomez-Arbelaez et al.18
Woehl et al.19

2
3
3
1
4
4

Katchanov et al.20
Wickham et al.21

1
1

Descending aorta (2), aortic arch (1)
Aortic arch (1), ascending aorta (1), descending aorta (2)
Abdominal aorta with extension to both iliac arteries (3)
Ascending aorta (1)
Aortoiliac (2), aortic arch (1), descending thoracic aorta (1)
Descending aorta (1), abdominal aorta (1), abdominal aortic with extension to
both iliac arteries (1), abdominal aorta with extension to the right iliac artery (1)
Lower thoracic aorta with extension to the abdominal aorta and both iliac arteries (1)
Lower thoracic aorta (1)

a

Some patients had a thrombosis in multiple locations.

In our patient, we see an example of arterial
thrombosis in the aortic arch extending into the
descending aorta. Although the aorta is not a typical
location to experience thrombotic disease, due to the
hypercoagulability of COVID-19, it is fairly common
to ﬁnd thrombi in atypical locations. We reviewed
eight articles that described 19 cases involving aortic
thrombosis in COVID-19 patients. Table 4 summarizes the locations of thrombosis within the aorta as
reported in these case studies.14e21 Of the 19 cases,
three patients experienced a stroke, nine experienced acute limb ischemia, two experienced acute
mesenteric ischemia, two experienced acute kidney
infarction, some patients had more than one
complication, and ﬁve patients were asymptomatic.
There is enough evidence to prove that aortic
thrombosis can have diverse presentations, ranging
from asymptomatic to severe and life-threatening
complications. Although this pathology is usually
considered rare, it needs to be kept in mind when
treating COVID-19 patients for prevention or early
intervention of these complications.

4. Conclusion
Reﬂecting on our case report and the information
we gathered, we know that a delayed diagnosis
makes arterial thrombosis a lethal complication in
COVID-19 patients. Since vigilant monitoring of
symptoms and procoagulant labs, and timely intervention prevents thromboembolic complications in
patients, it is important to keep an eye out for these

to reduce morbidity and mortality. Since imaging
has a potential role in screening and early diagnosis
of thromboembolism in COVID-19 patients, imaging frequency should be individualized for the patients based on a risk-beneﬁt analysis. Additionally,
more research needs to be conducted to assess the
best level and type of anticoagulation used in
COVID-19 patients based on the risk factors and
severity of the disease. It is important to note an
increased incidence of confusion associated with the
COVID-19 patient population, especially in those
with increased isolation status. Hence, it would be
useful to use anticoagulants whose serum levels can
be monitored, such as warfarin instead of Eliquis or
Xarelto. COVID-19 is still a relatively new disease
and continues to be elusive in its presentation and
course. Newer complications and difﬁculties with
management emerge every day. Persistent observation, research, and reﬂection from all of us would
help improve patient care.
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